Option Fee

(redirected from Option Fees)

Option Fee

In Texas, a fee the potential buyer of real estate may pay the seller in exchange for the agreement not to sell to anyone other than the potential buyer for a (usually short) period of time. An option fee should not be confused with earnest money, which is related but different.
Mentioned in ?
References in periodicals archive ?
Under the exclusive license agreement, Heidelberg Pharma would be eligible to receive option fees, clinical development, regulatory and sales-related milestone payments up to USD334 m, if Magenta exercises all target options and all milestones are met.
The biopharma company will also have the option to gain US rights to projects resulting from the collaboration, which will be based on payment of additional option fees.
Warp Drive will retain worldwide rights to all other novel antibiotic classes from the collaboration Warp Drive will receive up to $87 million in upfront payment, option fees, and milestone payments for preclinical events, and up to $300 million in payments related to specific clinical, regulatory and sales milestones on products licensed to Roche.
Precision BioSciences will receive an upfront payment of $105 million, with additional option fees, development, clinical, regulatory, and sales milestones, potentially totaling as much as $1.
However, individual projects chosen to go forward will trigger option fees and the partners will negotiate further research and licence agreements, the Anglo-Swedish pharma major said.
Normal membership conditions, standard rental periods and extra night option fees apply.
The department, Campbell noted, has proposed regulations that would provide plan administrators with a more thorough breakdown of plan and investment option fees.
Other detailed terms of the agreements, including option fees, license fees and license royalties, are confidential.
Ablynx will receive an upfront payment of EUR23m, comprised of licence and option fees.
Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $45 million and will be eligible to receive up to an additional approximately $965 million in contingent option fees and milestone payments related to specified research, preclinical, clinical, regulatory and sales-based milestones across all five potential programs.
6 billion in option fees and milestones over the long-term, as well as royalties on sales.
The contract covers USD8m upfront fee and around EUR100m in option fees, clinical and regulatory milestones and sales-based royalties on licensed products.